STOCK TITAN
  1. Home
  2. News
  3. XFOR

X4 Pharmaceuticals Inc - XFOR STOCK NEWS

Welcome to our dedicated news page for X4 Pharmaceuticals (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect X4 Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of X4 Pharmaceuticals's position in the market.

News
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
X4 Pharmaceuticals (Nasdaq: XFOR) issued 1,164,470 inducement awards to new employees under the 2019 Inducement Equity Incentive Plan. Each option has a ten-year term, an exercise price of $1.41 per share, and vests over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
none
-
News
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
Rhea-AI Summary
X4 Pharmaceuticals (XFOR) will participate in the Needham 23rd Annual Healthcare Conference and Piper Sandler Spring Biopharma Symposium to showcase advancements in rare disease treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
conferences
-
News
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
X4 Pharmaceuticals prepares for the possible U.S. approval of mavorixafor for WHIM syndrome with a PDUFA target action date set for April 30, 2024. The company reported financial results for Q4 and full year 2023, highlighting key events and upcoming milestones. X4 expects a transformative year in 2024 with the submission of an NDA for WHIM syndrome treatment, clinical proof of concept for chronic neutropenia, and initiation of a Phase 3 clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.43%
Tags
earnings
News
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024
Rhea-AI Summary
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) will report financial results for Q4 and full year 2023 on March 21, 2024, with a conference call and webcast. Investors can access the call and webcast through the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.24%
Tags
conferences earnings
-
News
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
X4 Pharmaceuticals issues inducement awards to new employees under the 2019 Inducement Equity Incentive Plan. The awards consist of options to purchase 1,524,112 shares of X4's common stock at an exercise price of $0.9710 per share. Each option will vest over a four-year period, with 25% vesting after 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
none
-
News
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
X4 Pharmaceuticals (Nasdaq: XFOR) issued inducement awards to new employees under the 2019 Inducement Equity Incentive Plan, granting options to purchase 575,942 shares of X4's common stock. The options have a ten-year term with an exercise price of $0.7814 per share, vesting over a four-year period, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
none
News
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023
Rhea-AI Summary
X4 Pharmaceuticals (Nasdaq: XFOR) announced the presentation of additional preliminary data from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of once-daily oral mavorixafor with or without concurrent treatment with injectable granulocyte-colony stimulating factor (G-CSF) in people diagnosed with idiopathic, cyclic, or congenital neutropenia. The data continue to support the potential of mavorixafor to raise absolute neutrophil counts (ANC) and enable reduction in G-CSF dosing in patients with chronic neutropenia. The trial is expected to initiate in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
X4 Pharmaceuticals (Nasdaq: XFOR) issued 114,500 inducement awards to new employees under the 2019 Inducement Equity Incentive Plan. The options have a ten-year term, with an exercise price of $.78 per share, vesting over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.88%
Tags
none
-
News
X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences
Rhea-AI Summary
X4 Pharmaceuticals (XFOR) to participate in fireside chats at Stifel Healthcare Conference on November 14-15, 2023, and Piper Sandler 35th Annual Healthcare Conference on November 28-30, 2023. The management will engage in discussions about the company's initiatives in rare diseases of the immune system, emphasizing its commitment to improving patients' lives. Webcast links provided for both events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
conferences
News
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates
Rhea-AI Summary
X4 Pharmaceuticals (XFOR) reports FDA acceptance of New Drug Application for mavorixafor in WHIM syndrome, with a PDUFA target action date of April 30, 2024. Additional data from ongoing Phase 2 clinical trial of mavorixafor in chronic neutropenia expected in 4Q 2023 and 1H 2024. Company prepares for a possible U.S. launch in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.61%
Tags
earnings
Stock XFOR logo
X4 Pharmaceuticals Inc

Nasdaq:XFOR

XFOR Rankings

#3645 Ranked by Market Cap
#4974 Ranked by Stock Gains
N/A Ranked by Dividends

XFOR Stock Data

225.04M
130.20M
0.83%
61.32%
7.34%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Boston

About XFOR

x4 pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking and reverse immune suppression, which is fundamental to treating cancer and certain rare, genetic primary immunodeficiency diseases. our oral, small molecule drug candidates inhibit the binding of chemokine cxcl12 to c-x-c receptor type 4 (cxcr4), a receptor-ligand pair that plays an essential role in normal immune surveillance. we are committed to advancing the fields of cancer immunotherapy and genetic immune disorders through innovation and investment in our proprietary clinical and preclinical pipeline. x4’s most advanced product candidate, x4p-001-rd, is in a phase 2/3 study in patients with whim syndrome, a rare genetic, primary immunodeficiency disease. x4p-001-io is currently under investigation in multiple phase 1/2 studies in refractory clear cell renal cell carcinoma (ccrcc) and melanoma. our third program, x4p-002, is in preclinical development and designed specifically for the t